Back

Effects of semaglutide and dapagliflozin on natriuretic peptides in type 2 diabetes: a randomized comparative study

28 August 2026 (10:15 - 11:00)
Organised by: Logo
Congress Presentation Part of: Diabetes and the heart: pharmacotherapy (1) Pharmacotherapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Carl Lejonberg

Internal Medicine, Helsingborg (Sweden)

6 More presentations in this session

Presentation thumbnail
Efficacy of Semaglutide in glycemic control, weight loss, and improving lipid profile- the role of baseline vitamin D levels.
Professor R. Abo Fanne (Hadera, IL)
Abstract Slides Video
Presentation thumbnail
The association between SGLT2 inhibitors and new-onset osteoporosis in patients with type 2 diabetes: a population-based longitudinal cohort study
Doctor C. Chang (Taichung, TW)
Abstract Slides Video
Presentation thumbnail
Statin therapy for primary prevention of microvascular complications in patients with heart failure and type 2 diabetes: a target trial emulation
Miss A. Matsumoto (HK)
Abstract Slides Video
Presentation thumbnail
Parallel disease trajectories of peripheral neurovascular disease and heart failure in type 2 diabetes mellitus: a 12-year prospective follow-up
Doctor D. Andric (Novi Sad, RS)
Abstract Slides Video
Presentation thumbnail
Suboptimal cardioprotective medication prescribing in patients with diabetes and stage B heart failure
Mr M. Hussain (Dundee, GB)
Abstract Slides Video

Access the full session

Session thumbnail
Diabetes and the heart: pharmacotherapy (1)

The Event

Event poster

ESC Congress 2026

28 August 2026 10:15 CET
You may be interested in
thumbnail
Congress Presentation
Short-term effects of dapagliflozin versus canagliflozin on acute decompensated heart failure in patients with type 2 diabetes
2 September 2019
thumbnail
Webinar
Natriuretic peptides: role for risk prediction and treatment efficacy
7 October 2021
thumbnail
Congress Presentation
Blood pressure effect of semaglutide in patients with hypertension: an individual patient data analysis of randomised controlled trials
25 April 2024
thumbnail
Webinar
GLP-1 RAs and HFpEF : what do we know from large RCTs about GLP-1 RAs and their effects on HFpEF?
24 November 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources